Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 8, 2015, Pages 979-989

  Rödel, Claus ^a,b   Graeven, Ullrich ^c   Fietkau, Rainer ^d   Hohenberger, Werner ^d   Hothorn, Torsten ^d,e   Arnold, Dirk ^f   Hofheinz, Ralf Dieter ^g   Ghadimi, Michael ^h   Wolff, Hendrik A ^h   Lang Welzenbach, Marga ^d   Raab, Hans Rudolf ⁱ   Wittekind, Christian ^j   Ströbel, Philipp ^h   Staib, Ludger ^k   Wilhelm, Martin ^l   Grabenbauer, Gerhard G ^m   Hoffmanns, Hans ^c   Lindemann, Fritz ⁿ   Schlenska Lange, Anke ^o   Folprecht, Gunnar ^p   Sauer, Rolf ^d   Liersch, Torsten ^o   more..

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KLINIKEN MARIA HILF GMBH   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f TUMOR BIOLOGY CENTER   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF OLDENBURG   (Germany)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k KLINIKUM ESSLINGEN   (Germany)

^l KLINIKUM NÜRNBERG   (Germany)

^m DiaCura and Klinikum Coburg   (Germany)

ⁿ Department of General and Visceral Surgery ^*  (Germany)

^o KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^p UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS STENOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; FECES INCONTINENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; RECTUM SURGERY; SENSORY NEUROPATHY; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; GERMANY; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; RECTAL NEOPLASMS; SECONDARY; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938211714     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00159-X     Document Type: Article

References (35)

1. Heald RJ, Ryall RD Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1:1479-1482.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
3. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820.
4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
5. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
6. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26:3687-3694.
7. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
8. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011, 12:575-582.
9. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 2012, 30:1926-1933.
10. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II and III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
11. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011, 29:3768-3774.
12. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21:3098-3104.
13. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25:110-117.
14. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012, 13:679-687.
15. International Union Against Cancer TNM classification of malignant tumours 2002, John Wiley & Sons, Hoboken, NJ. 6th edn. L.H. Sobin, C. Wittekind (Eds.).
16. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009, 373:821-828.
17. Schmiegel W, Pox C, Adler G, et al. S3-guidelines conference "colorectal carcinoma" 2004. Z Gastroenterol 2004, 42:1129-1177. (in German).
18. R: a language and environment for statistical computing, version 3.1-2 R Development Core Team, (accessed Oct 11, 2014). http://CRAN.R-project.org.
19. Therneau T coxme: mixed effects Cox models, R package version 2.2-3 (accessed July 16, 2014). http://CRAN.R-project.org/package=coxme.
20. Gerds TA prodlim: product-limit estimation, R package version 1.4.5 (accessed Sept 3, 2014). http://CRAN.R-project.org/package=prodlim.
21. Hothorn T, Hornik K, van de Wiel MA, et al. A Lego system for conditional inference. Am Stat 2006, 60:257-263.
22. Gray B cmprsk: subdistribution analysis of competing risks. R package version 2.2-7 (accessed July 16, 2014). http://CRAN.R-project.org/package=cmprsk.
23. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011, 29:2773-2780.
24. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28:1638-1644.
25. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014, 32:1927-1934.
26. Schmoll HJ, Haustermans K, Rice TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival at interim analysis. Proc Am Soc Clin Oncol 2014, 32. abstract 3501.
27. Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012, 30:4558-4565.
28. Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014, 15:1245-1253.
29. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014, 25:1356-1362.
30. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015, 16:200-207.
31. NCCN clinical practice guidelines in oncology, rectal cancer, I, version (accessed Sept 12, 2014). http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
32. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010, 11:835-844.
33. Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014, 32:1554-1562.
34. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012, 13:579-588.
35. Chand M, Swift RI, Tekkis PP, Chau I, Brown G Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 2014, 110:19-25.